Company Profile:

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics (TPTs). The companys advanced TPTs are in clinical development for cancers, which have significant unmet needs for patients. It is developing Vicinium that is in active Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for late stage squamous cell carcinoma of the head and neck, preparing for a Phase 2 clinical trial in combination with cancer immunotherapy. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Recent News:

On March 24, 2017, the company reported that revenue was $0.8 million for the three months ended December 31, 2016, compared to $0.6 million for the same period in 2015. Net loss was $3.5 million, or $0.15 per share, for the three months ended December 31, 2016, compared to net loss of $10.3 million, or $0.53 per share, for the same period in 2015.

On Nov. 14, 2016, the company reported revenue was $28.7 million for the three months ended September 30, 2016, compared to $0.1 million for the same period in 2015. Net income was $19.5 million, or $0.95 per basic share and $0.91 per diluted share, for the three months ended September 30, 2016, compared to a net loss of $9.7 million, or $0.50 per basic and diluted share, for the same period in 2015.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

EBIO’s strengths can be seen in its better growth compared with its peers. Technical indicators signal the bullish signs, as MACD goes green, there is a bullish crossover in Stochastic Oscillator and RSI stands at 52.11 with positive bias. We rate Eleven Biotherapeutics, Inc. (EBIO) a STRONG BUY.